Exzeo Group prices IPO at $21 per share, raising $168 million

Investing.comTuesday, November 4, 2025 at 11:41:03 PM
Exzeo Group prices IPO at $21 per share, raising $168 million
Exzeo Group has successfully priced its initial public offering at $21 per share, raising an impressive $168 million. This move marks a significant milestone for the company as it enters the stock market, attracting investor interest and setting the stage for future growth.
— Curated by the World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
HCI-Backed Insurtech Firm Exzeo Group Raises $168 Million in IPO
PositiveFinancial Markets
Exzeo Group Inc., an insurtech firm supported by HCI Group Inc., successfully raised $168 million in its initial public offering, pricing at the midpoint of its marketed range. This achievement comes as the company joins a select group of firms going public amid the ongoing government shutdown.
Sera prognostics CIO Harrison sells $6.1k in shares
NeutralFinancial Markets
Harrison, the CIO of Sera Prognostics, has sold shares worth $6.1k. This transaction is part of regular trading activities and does not indicate any significant changes within the company.
Agilysys (AGYS) CFO Wood sells $123,393 in shares
NeutralFinancial Markets
Agilysys CFO Wood has sold shares worth $123,393, reflecting a routine financial decision. This move is part of standard practices in corporate finance, where executives manage their stock holdings.
India’s ChrysCapital Raises Its Largest Fund With $2.2 Billion
PositiveFinancial Markets
ChrysCapital Management Co. has successfully closed its largest private equity fund at $2.2 billion, surpassing its previous record. This significant milestone positions the firm to pursue more investment opportunities in the industrials and health care sectors.
Carvana VP Palmer sells $305,000 in shares
NeutralFinancial Markets
Carvana's VP, Palmer, has sold $305,000 worth of shares. This transaction is part of the company's ongoing financial activities and reflects the current market conditions.
Earnings call transcript: Allegiant Travel Co. misses Q3 2025 earnings mark
NegativeFinancial Markets
Allegiant Travel Co. has reported disappointing earnings for the third quarter of 2025, missing market expectations. The earnings call revealed challenges the company faced, which may impact its future performance.
Zeta Global shares soar as revenue beats estimates, raises outlook
PositiveFinancial Markets
Zeta Global's shares have surged after the company reported revenue that exceeded expectations and raised its outlook for the future. This positive news has boosted investor confidence and reflects the company's strong performance in the market.
Kyndryl shares soar as company reaffirms outlook despite revenue miss
PositiveFinancial Markets
Kyndryl's shares have surged as the company confidently reaffirms its outlook, even in the face of a revenue miss. This positive response from the market highlights investor trust in Kyndryl's long-term strategy and potential for growth.
Latest from Financial Markets
Private-Credit Earnings Ease Investor Concern Over Asset Class’s Health
PositiveFinancial Markets
Apollo CEO Marc Rowan has reassured investors by addressing concerns regarding the health of the private-credit asset class, easing worries and highlighting the stability of the sector.
Private-Credit Earnings Ease Investor Concern Over Asset Class’s Health
PositiveFinancial Markets
Apollo CEO Marc Rowan has reassured investors by addressing concerns regarding the health of the private-credit asset class, easing worries and highlighting the sector's resilience.
Aviat Networks Q1 FY2026 slides: Revenue jumps 21.4%, exceeding expectations
PositiveFinancial Markets
Aviat Networks reported a remarkable 21.4% increase in revenue for Q1 FY2026, surpassing market expectations. This growth highlights the company's strong performance and positive outlook in the telecommunications sector.
Stoke Therapeutics Q3 2025 presentation: strong revenue growth amid clinical progress
PositiveFinancial Markets
Stoke Therapeutics recently presented its Q3 2025 results, showcasing impressive revenue growth alongside significant advancements in its clinical programs. The company's progress highlights its commitment to developing innovative therapies, making it a key player in the biotechnology sector.
Amgen Q3 2025 slides: Revenue up 12%, guidance raised on strong product performance
PositiveFinancial Markets
Amgen has reported a 12% increase in revenue for Q3 2025, prompting the company to raise its guidance due to strong product performance. This positive trend highlights the effectiveness of their strategies and the growing demand for their offerings.
Corsair Q3 2025 slides show strong growth amid missed earnings forecasts
NeutralFinancial Markets
Corsair's Q3 2025 slides indicate a strong growth trajectory, despite missing earnings forecasts. The company is navigating challenges while showcasing resilience in its performance.